Early Detection of Alzheimer's Disease

Alzheimer's disease (AD) is the most common form of dementia. According to the WHO, AD accounts for 60-70% of cases of dementia. Timely diagnosis can significantly improve quality of life and treatment outcomes.

Early detection of Alzheimer's pathology is now possible through advanced blood testing. Speak with your doctor about which test is right for you.

Order Now

The Alzheimer's Disease Timeline

Preclinical Stage (10-20 years before symptoms)

Brain changes begin but no noticeable symptoms. Ideal time for intervention.

Mild Cognitive Impairment (MCI)

Subtle symptoms appear but daily function remains largely intact.

Dementia Stage

Significant cognitive decline affecting daily life. Most current diagnoses occur at this late stage.

If you have an APOE4 allele, your risk of developing Alzheimer’s disease is 2 to 3 times higher than the general population;

And if you have two APOE4 alleles, your risk of developing AD is 10 to 15 times higher than the general population.

Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18, 421–430 (2016).

Non-invasive blood biomarker tests, such as plasma p-tau217 are now included in clinical guidelines.

A high level of plasma p-tau217 is strongly indicative of Alzheimer's disease.

Jack Jr, C. R., Andrews, J. S., Beach, T. G., et. al. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia, 20(8), 5143-5169.

Why choose non-invasive tests?

High Diagnostic Accuracy

Plasma p-Tau217 demonstrates superior sensitivity and specificity in diagnosing Alzheimer’s disease when compared to traditional methods.

Early Intervention

Current treatments are most effective when started early in the disease process, potentially slowing cognitive decline.

Disease monitoring

Non-invasive blood tests such as p-Tau217 and Aβ42/40 ratio allows doctors to monitor Alzheimer's disease progression.

CSF Testing

Analyze cerebrospinal fluid (CSF) for biomarkers.

Traditional standard for amyloid and tau pathology
Invasive procedure
Expensive

Amyloid PET Scan

Imaging test that detects amyloid plaques in the brain.

Imaging confirmation of amyloid
Radiation exposure
Expensive

p-Tau 217 test

A blood biomarker test that has strong association with AD

Accurate ¹
Non-invasive
Affordable

Product Comparison

	Alzheimer’s Disease-related tests
	CoGenesis® AD	APOE test	p-Tau 217	Aβ42/40
Biomarker(s) tested	APP, PSEN1, PSEN2, APOE, TREM2, MAPT	APOE	p-Tau 217	Aβ40, Aβ42
Target of service	People who have been diagnosed with early-onset Alzheimer’s disease People who are suspected of having early-onset Alzheimer’s disease People with family members with early-onset Alzheimer’s disease	People who have been diagnosed with late-onset Alzheimer’s disease People who are suspected of having late-onset Alzheimer’s disease People with family members with Alzheimer’s disease	People who have been diagnosed with late-onset Alzheimer’s disease People who are suspected of having late-onset Alzheimer’s disease People with family members with Alzheimer’s disease	People who have been diagnosed with late-onset Alzheimer’s disease People who are suspected of having late-onset Alzheimer’s disease Indicate amyloid deposition in the brain

Order Now

Fast and accurate confirmatory diagnosis of disease

Biomarker evidence may provide additional diagnostic certainty of Alzheimer's disease.

Discover treatment options

The U.S. Food and Drug Administration approved lecanemab and donanemab as the treatment of Alzheimer’s disease. However, people with the APOE4 gene for Alzheimer’s may have a higher risk side effects. Knowing the APOE genotype may assist in personalizing treatments.

The process

1

Contact us and visit one of the partnering clinics.

2

Standard blood draw procedure, just like routine lab tests.

3

Specialized lab measure p-Tau217 levels, amyloid beta 42/40 ratio or APOE genotypes using ultrasensitive assays.

4

Results are interpreted by specialists and provided with clinical context.

A high accuracy standard

Test	Sensitivity	Specificity
APOE genotyping	99.9%^*^#	99.9%^*^#
p-Tau217	94.6%¹	91.9%¹
Aβ42/40	84.0%²	81.8%²

* Passed GenQA/UK NEQAS external quality assurance

¹ Wang, X., et.al. (2024). Alzheimer's Research & Therapy, 16(1), 82.
² Schindler, S. E., et.al. (2019). Neurology, 93(17), e1647-e1659.

# The interpretation of sequencing variants is based on the current understanding of the variants at the time it was observed, which may change over time as more information about the genes becomes available. Not all variants are represented in this report.

More neurology test services

CoGenesis^® Neuro

Screening for 505 neuro disease genes in one test

Explore CoGenesis® Neuro

CoGenesis^® Myopathy

Screening for 108 myopathy-related genes in one test

Explore CoGenesis® Myopathy

Genetic tests for Spinocerebellar Ataxia

Covers individual or multiple common Spinocerebellar Ataxia (SCA) subtypes

Explore SCA tests

The services provided by Codex Genetics are for research use only, and they are not suitable for diagnostic and/or treatment use, unless otherwise instructed by licensed medical professionals.

除非有醫療專業人員另行指示，此網站的服務只供研究用途，並不供作診斷或治療任何疾病之用。

Alzheimer's disease (AD) is the most common form of dementia. According to the WHO, AD accounts for 60-70% of cases of dementia. Timely diagnosis can significantly improve quality of life and treatment outcomes.

Early detection of Alzheimer's pathology is now possible through advanced blood testing. Speak with your doctor about which test is right for you.

The Alzheimer's Disease Timeline

Preclinical Stage (10-20 years before symptoms)

Mild Cognitive Impairment (MCI)

Dementia Stage

If you have an APOE4 allele, your risk of developing Alzheimer’s disease is 2 to 3 times higher than the general population;

And if you have two APOE4 alleles, your risk of developing AD is 10 to 15 times higher than the general population.

Non-invasive blood biomarker tests, such as plasma p-tau217 are now included in clinical guidelines.

A high level of plasma p-tau217 is strongly indicative of Alzheimer's disease.

Why choose non-invasive tests?

High Diagnostic Accuracy

Plasma p-Tau217 demonstrates superior sensitivity and specificity in diagnosing Alzheimer’s disease when compared to traditional methods.

Early Intervention

Current treatments are most effective when started early in the disease process, potentially slowing cognitive decline.

Disease monitoring

Non-invasive blood tests such as p-Tau217 and Aβ42/40 ratio allows doctors to monitor Alzheimer's disease progression.

CSF Testing

Amyloid PET Scan

p-Tau 217 test

Product Comparison

Fast and accurate confirmatory diagnosis of disease

Biomarker evidence may provide additional diagnostic certainty of Alzheimer's disease.

Discover treatment options

The U.S. Food and Drug Administration approved lecanemab and donanemab as the treatment of Alzheimer’s disease. However, people with the APOE4 gene for Alzheimer’s may have a higher risk side effects. Knowing the APOE genotype may assist in personalizing treatments.

The process

1

Contact us and visit one of the partnering clinics.

2

Standard blood draw procedure, just like routine lab tests.

3

Specialized lab measure p-Tau217 levels, amyloid beta 42/40 ratio or APOE genotypes using ultrasensitive assays.

4

Results are interpreted by specialists and provided with clinical context.

A high accuracy standard

More neurology test services

CoGenesis® Neuro

Screening for 505 neuro disease genes in one test

CoGenesis® Myopathy

Screening for 108 myopathy-related genes in one test

Genetic tests for Spinocerebellar Ataxia

Covers individual or multiple common Spinocerebellar Ataxia (SCA) subtypes

Pinpointing genetic uniqueness

CoGenesis^® Neuro

CoGenesis^® Myopathy